|
View web version
|
|
|
EXPLORE THE
|
|
POTENTIAL
|
|
OF A NOVEL APPROACH TO
|
|
PULMONARY ARTERIAL HYPERTENSION (PAH)
|
|
|
|
Learn more about BMPR2 signaling in PAH
|
|
We invite you to visit Booth #808
|
|
at the American Thoracic Society 2019 International Conference, May 17-22, 2019, in Dallas, Texas, for a 3D experience that will introduce
you to the science of sotatercept, our investigational drug candidate directed at rebalancing BMPR2 signaling in pulmonary arterial
hypertension (PAH). While you’re there, you’ll also learn about our ongoing Phase 2 clinical trials, which are investigating the effects of
sotatercept in PAH.
|
|
Acceleron is passionate about accelerating the discovery and development of transformative treatments for patients with PAH and other rare diseases.
|
|
|
Learn about our
|
|
Phase 2 clinical trials in PAH
|
|
|
|
|
If you have any questions about our clinical trials, eligibility, enrollment, or our pulmonary pipeline, feel free to contact us at clinicaltrials011@acceleronpharma.com.
|
|
|
|
Sotatercept is an investigational therapy that is not approved for any use in any country.
|
|
This message was sent by Acceleron Pharma, Inc.
|
Acceleron Pharma, Inc.
128 Sidney Street
Cambridge, MA 02139
USA
|
|